Antibiotic synergy with enterococcal endocarditis experienced a high relapse rate when penicillin G alone was used for treatment and a demonstrably lower relapse rate when streptomycin was combined with penicillin G to combat the infection. Since that time the research community has conducted numerous studies regarding the effects and possibilities of antibiotic combinations. Today, combination therapy is recognized as providing a broad spectrum of antibiotic coverage, effectively fighting polymicrobial infections, minimizing selection for antibiotic resistant strains, lowering dose toxicity where applicable, and in some cases providing synergistic activity. Antibiotic synergy is desirable in a clinic sense for several reasons. At the patient
Antibiotic use in livestock for not collecting enough information and data on antibiotic use in factory farms. From this, the GAO concluded that the FDA does not have enough information to create effective policy changes regarding antibiotic use. In response, the FDA insisted that more research was being conducted and voluntary efforts within the industry would solve the problem of antibiotic resistance. Few policies exist that limit antibiotic use on factory farms, and some proposed legislation in the US has failed to be adopted. In 2007, two federal bills (S. 549 and H.R. 962) aimed to phase out nontherapeutic antibiotics in U.S. food animal